Relay Therapeutics, Inc. (RLAY)
18.51
+0.02
(+0.11%)
USD |
NASDAQ |
Sep 02, 16:00
18.52
+0.01
(+0.05%)
After-Hours: 20:00
Relay Therapeutics Research and Development Expense (Annual) : 261.38M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 261.38M |
| December 31, 2024 | 319.09M |
| December 31, 2023 | 330.02M |
| December 31, 2022 | 246.36M |
| Date | Value |
|---|---|
| December 31, 2021 | 169.53M |
| December 31, 2020 | 96.97M |
| December 31, 2019 | 67.90M |
| December 31, 2018 | 39.33M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| AbbVie, Inc. | 8.249B |
| TG Therapeutics, Inc. | 160.22M |
| Karyopharm Therapeutics, Inc. | 125.32M |
| Krystal Biotech, Inc. | 52.32M |
| Akebia Therapeutics, Inc. | 61.09M |